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Hemophagocytic lymphohistiocytosis (HLH) is characterized by immune dysregulation due to inadequate restraint of
overactivated immune cells and is associated with a variable clinical spectrum having overlap with more common
pathophysiologies. HLH is difficult to diagnose and can be part of inflammatory syndromes. Here, we identify a novel
hematological/autoinflammatory condition (NOCARH syndrome) in four unrelated patients with superimposable features,
including neonatal-onset cytopenia with dyshematopoiesis, autoinflammation, rash, and HLH. Patients shared the same de novo
CDC42 mutation (Chr1:22417990C>T, p.R186C) and altered hematopoietic compartment, immune dysregulation, and
inflammation. CDC42mutations had been associated with syndromic neurodevelopmental disorders. In vitro and in vivo assays
documented unique effects of p.R186C on CDC42 localization and function, correlating with the distinctiveness of the trait.
Emapalumab was critical to the survival of one patient, who underwent successful bone marrow transplantation. Early
recognition of the disorder and establishment of treatment followed by bone marrow transplant are important to survival.
.............................................................................................................................................................................
1Department of Pediatrics, Baylor College of Medicine, Houston, TX; 2Department of Pediatrics, Columbia University, Irving Medical Center, New York, NY; 3National
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Introduction
The diagnosis and delineation of novel genetic syndromes is
often difficult given the limited availability of patients, genetic
heterogeneity, and clinical variability. Hemophagocytic lym-
phohistiocytosis (HLH) has recently been characterized as a
clinical syndrome with hyperinflammation driven by excessive
activation and expansion of macrophages and CD8+ T lympho-
cytes (Jordan et al., 2011; Rosado and Kim, 2013). Typical features
include persistent high fever, liver involvement, splenomegaly,
intravascular activation of coagulation associated with pancy-
topenia, and usually an increase in ferritin. Although this syn-
drome is clinically unique, the mechanisms underlying this
disorder are diverse (Sepulveda and de Saint Basile, 2017; Chinn
et al., 2018). Mutations leading to defective cytotoxicity by
natural killer (NK) and CD8+ T lymphocytes are the typical cause
of monogenic HLH, typically termed primary HLH. However, a
markedly higher number of patients present with HLH in the
absence of genetically defective cytotoxicity in the context of
infections, rheumatic inflammatory diseases and malignancy.
HLH in its various forms, both in children and adults, is in-
variably fatal if untreated.
Cell division cycle 42 (CDC42) is a member of the Ras-
homologous (Rho) GTPase family functioning as a signaling
node controlling a number of cellular processes, including
adhesion, migration, polarity, cell cycle, and proliferation
(Zhou et al., 2013; Baschieri et al., 2014). CDC42 functions as a
molecular switch by cycling between a guanosine 59-
triphosphate (GTP)–bound (active) and a guanosine diphos-
phate (GDP)–bound (inactive) state. Two CDC42 isoforms
have been characterized. While isoform 1 is ubiquitously ex-
pressed, isoform 2 is primarily found in the brain. CDC42
function is controlled by three different classes of regulators:
guanine nucleotide exchange factors (GEFs), GTPase-
activating proteins (GAPs), and guanine nucleotide dissocia-
tion inhibitors (Dvorsky and Ahmadian, 2004). The GTPase
primarily acts through its spatial and temporal localized in-
teraction with multiple downstream effectors, such as IQGAP1,
p21-activated kinase (PAK), and Wiskott–Aldrich syndrome
protein (WASP). Reversible localization of CDC42 at the cyto-
plasmic leaflet of the plasma membrane and other intracellular
membranes is regulated by Rho GDP-dissociation inhibitor
(RhoGDI) and IQGAP1. The former controls the dynamic
membrane–cytoplasm shuttling of the GTPase (Gibson and
Wilson-Delfosse, 2001; Gibson et al., 2004), while the latter
promotes CDC42 translocation from the Golgi apparatus to the
plasma membrane (Swart-Mataraza et al., 2002). These regu-
latory events play a crucial role in controlling CDC42 function,
cytoskeletal rearrangement, cell polarity, and migration. No-
tably, altered binding of CDC42 to IQGAP1 induces multiple
leading edge formation and aberrant multipolarized morphol-
ogy (Fukata et al., 2002). Actin rearrangements and cell mi-
gration are also promoted by CDC42 interaction with its
effector, WASP, a critical actin regulator and mediator of NK
cell cytotoxicity (Orange et al., 2002; Ridley et al., 2003). Fi-
nally, CDC42 function requires posttranslational processing
at the C-terminus, including prenylation at Cys188 (geranyl-
geranylation, most commonly) followed by proteolytic cleavage
of the last three residues and carboxyl-methylation (Aicart-
Ramos et al., 2011).
We and others recently identified germline heterozygous
mutations in CDC42 as the event underlying a remarkably het-
erogeneous collection of neurodevelopmental phenotypes
(Takenouchi et al., 2015; Martinelli et al., 2018). Core clinical
features of these traits include variable growth dysregulation;
facial dysmorphism; intellectual disability; cardiac defects; im-
munological, hematological, and lymphatic abnormalities; and
brain malformations. Mutations were found to variably disrupt
CDC42 function by altering the switch between the active and
inactive states of the GTPase and/or affecting its interaction
with effectors (Martinelli et al., 2018). As a result, multiple cel-
lular and developmental processes were differentially perturbed.
Remarkably, the biochemical and functional characterization of
mutations allowed the identification of genotype–phenotype re-
lationships, suggesting a link between the specific impact of in-
dividual mutation class and its phenotypic expression (Martinelli
et al., 2018). Mutations were documented to behave either as
activating or inactivating, with the latter specifically associated
with thrombocytopenia. Multisystem/organ involvement oc-
curred in all groups.
Using whole-exome sequencing/whole-genome sequenc-
ing (WES/WGS) coupled to biochemical and functional vali-
dation, we describe a novel hematological and autoinflammatory
phenotype in four unrelated patients caused by the same de
novo missense mutation of CDC42 (NM_001791, c.556C>T,
p.R186C). The disease differs considerably from those previ-
ously associated with CDC42 mutations and is characterized
by neonatal onset of pancytopenia, autoinflammation, rash,
and episodes of HLH (NOCARH). Through in silico, in vitro,
and in vivo analyses, we describe the mechanism by which
this specific amino acid change affects CDC42 function, in-
tracellular signaling, and cellular and developmental pro-
cesses. Finally, we provide a clinical delineation of this
disorder and document the clinical response to IFN-γ and IL-
1β neutralization and hematopoietic stem cell transplantation
(HSCT).
Results
Clinical features of patients
The four unrelated patients included in the study showed a
superimposable previously unrecognized multisystem disease
characterized by neonatal onset of pancytopenia, persistent fe-
ver, skin rash, hepatosplenomegaly, and persistently elevated
inflammatory markers in the absence of any evidence of neu-
rodevelopmental involvement (Tables 1, S1, and S2; and Fig. 1 A).
A suspicion of neonatal-onset multisystem inflammatory disease
in three of the four patients led to treatment with IL-1 inhibitors
with incomplete improvement of fever and rash, but not cyto-
penia. In all cases, high chronic doses of glucocorticoids were
required to treat inflammation. All patients developed HLH,
which was fatal in three subjects. Based on the shared features,
we propose the term of NOCARH syndrome for this trait. A
detailed description of the patients’ clinical history is provided
in the Materials and methods.
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Genetic studies
Two patients (patient 1 [Pt 1] and Pt 3) were enrolled in the
Undiagnosed Disease Programs at the Ospedale Pediatrico
Bambino Gesù and Baylor-Hopkins Center for Mendelian Ge-
nomics (CMG) at Baylor College of Medicine and the NK cell
Evaluation and Research Program at Baylor and Columbia Uni-
versity. Using a trio-based WES strategy, a de novo missense
CDC42 change (NM_001791, Chr1:22417990, c.556C>T, p.R186C)
affecting an isoform 1–specific exon was identified as the only
candidate variant underlying the disorder in both subjects (Ta-
ble S3). Occurrence of mutations in genes known to be associated
with HLH or other immunological and hematologic disorders was
excluded. Similarly, there was no other rare substantively
damaging variant shared by the two patients. The missense
mutation had not previously been reported in the Exome Ag-
gregation Consortium/Genome Aggregation Database (gno-
mAD) and was predicted to be damaging by in silico tools
(Combined Annotation-Dependent Depletion [CADD] v1.3: 24.5,
and Mendelian clinically applicable pathogenicity [M-CAP]
v1.3: 0.0531). Based on this finding, a third patient (Pt 2) having
clinical features resembling those of the two previously studied
subjects underwent Sanger sequencing for the relevant CDC42
coding portion, revealing heterozygosity for the same c.556C>T
transition, which was validated to occur as a de novo event.
Finally, through networking, a fourth patient (Pt 4) sharing a
similar clinical phenotype, and the same de novo CDC42 mu-
tation was identified. In this case, the mutation was revealed by
WGS using a trio-based strategy (Table S3), which excluded the
occurrence of functionally and clinically relevant variants in
HLH- and autoinflammation-related genes.
Biochemical and functional studies
To explore the functional consequence of the identifiedmissense
change, we initially assessed CDC42 levels in primary fibroblasts
(Pt 1 and Pt 2) and HEK-293T cells transiently expressing the
FLAG-tagged CDC42 mutant. In primary fibroblasts, the protein
was expressed to similar levels without any apparent acceler-
ated degradation (Fig. 1 B). Similarly, no reduction in the level of
the mutant was observed in transfected cells. These data sug-
gested that the disease-associated missense change does not
significantly decrease CDC42 synthesis/stability, pointing to a
specific perturbing effect on protein function.
Compared with the previously identified variants of CDC42
underlying neurodevelopmental disorders (Takenouchi et al.,
2015; Martinelli et al., 2018), the p.R186C amino acid substitu-
tion occurs in a unique region at the C-terminus, within the
hypervariable region (Fig. 1 C). Specifically, Arg186 lies in
proximity of Cys188, which serves as substrate site for CDC42
prenylation. This irreversible posttranslational modification is
required for proper CDC42 subcellular localization and function.
To assess a possible effect of the p.R186C substitution on CDC42
prenylation, mass spectrometry (MS) analysis of the purified
CDC42 mutant was performed, revealing proper C-terminal
processing and lipid incorporation (Fig. 1 D), excluding the
possibility of a defective or aberrant CDC42 posttranslational
processing. Structural studies indicate that Arg186 is located far
from the GDP/GTP–binding pocket and major regions control-
ling CDC42 interaction with positive and negative regulators
(switch regions I and II; Phillips et al., 2008). Consistently,
fluorescence-based cell-free assays showed that replacement of
Arg186 by cysteine did not have a significant impact on either
CDC42 basal and GEF-catalyzed GDP/GTP exchange activity or
basal and GAP-stimulated GTPase activity of the protein
(Fig. 1 E).
Arg186 is a solvent-exposed residue located at the surface of
CDC42 in one of the two major sites of binding to RhoGDI
(Hoffman et al., 2000; Fig. 2 A). The residue stabilizes the
geranylgeranyl-mediated CDC42–RhoGDI interaction. This in-
teraction has a key role in the control of CDC42 function, as it
Table 1. Features of patients sharing the de novo missense CDC42
c.556C>T (p.R186C) mutation
Pt 1 Pt 2 Pt 3 Pt 4
Outcome and status Alive, 6 yr Dead, 6 mo Dead, 1.5 yr Dead, 4.5 mo
Fever + + + +
Skin rash + + + +
Facial dysmorphism − − − −
Failure to thrive + + + +
Hepatomegaly + + + +
Splenomegaly + + + −
CNS inflammatory
diseasea
+ − − −
Gastrointestinal
symptomsb
+ + + +
Cardiac abnormalities − − − −
HLHc + + + +
Anemiad + + + +
Thrombocytopeniad + + + +
Neutropeniae + + + +
Monocytopenia + + N/A N/A
Acute-phase
response
+ + + +
BM dysplasia + + + +
Other notable
features
+f − − +g
CNS, central nervous system; N/A, not applicable.
aPt 1, three episodes at age 2 yr with generalized seizures and white and gray
matter lesions in MRI; Pt 3, increased CSF protein and MRI with
leptomeningitis.
bPt 1, diarrhea, intestinal bleeding at age 11 mo, and intestinal infarction at
age 5 yr; Pt 2, chronic diarrhea; Pt 3, small intestine inflammation; Pt 4,
severe, unremitting enterocolitis from birth and diarrhea with intestinal
bleedings and infarctions.
cPt 1, four episodes; Pt 2, a single episode leading to death; Pt 3, died of
secondary HLH after transplant; Pt 4, four episodes.
dPt 1, constant transfusion requirement until age 2 yr; Pt 2, intermittent
transfusion requirement during flares; Pt 3, transfusion dependent; Pt 4,
transfusion dependent.
ePt 1, Pt 2, and Pt 3, profound neutropenia; Pt 4, mild neutropenia.
fSuspected trigonocephaly.
gVery small thymus; arthritis.
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negatively regulates stable binding of the GTPase to the cyto-
plasmic leaflet of membranes and modulates CDC42 trafficking
(Gibson and Wilson-Delfosse, 2001; Gibson et al., 2004). Based
on the predicted disruptive effect of the Arg-to-Cys substitution
on RhoGDI binding (Fig. 2 A), pull-down assays were performed
to confirm defective interaction between the CDC42 mutant and
RhoGDI (Fig. 2 B). The impaired binding of prenylated
CDC42R186C protein to RhoGDI was also demonstrated by surface
plasmon resonance (SPR) analysis (Fig. 2 C). These data strongly
suggest a perturbation of proper subcellular localization and
trafficking of CDC42 as a major event contributing to patho-
genesis. Notably, since other residues previously reported to be
mutated in CDC42-related neurodevelopmental disorders are
located at the interacting surface of the second major site of the
GTPase mediating binding to RhoGDI, with a subset of them
directly involved in RhoGDI binding (Fig. 2 A), the defective
binding of CDC42 to RhoGDI likely does not represent a dis-
tinctive impairment of the CDC42R186C mutant. This was con-
firmed by pull-down assays using a panel of bacterially
expressed mutants to assess the impact of amino acid sub-
stitutions in regions far from the C-terminal tail on RhoGDI
binding, which consistently with the structural data suggest that
other missense changes variably impact CDC42 binding to
RhoGDI (data not shown).
GTP-bound CDC42 activates multiple downstream signaling
pathways by interacting with a variety of effectors (Dvorsky and
Ahmadian, 2004; Nouri et al., 2017). We assessed the capability
of the CDC42R186C mutant to transduce signals by measuring its
direct binding to major effectors, including WASP, PAK1, and
IQGAP1. Glutathione S-transferase (GST) pull-down assays
coupled to immunoblotting demonstrated a decreased effector
binding of the mutant protein compared withWT CDC42, with a
significantly diminished binding to WASP and a dramatically
reduced interaction with IQGAP1 (Fig. 2 D). Given the estab-
lished role of RhoGDI and IQGAP1 in the control of the dynamic
redistribution of CDC42 within cells, we analyzed the possible
disruption of the subcellular localization of the CDC42R186C
protein by using complementary cellular models. Depending on
the cellular context and stimuli, CDC42 localizes to the cyto-
plasmic leaflet of multiple compartments, vesicles, and plasma
membrane and partly the cytoplasm (Valdés-Mora and Lacal,
2011). Surprisingly, a constitutive cis/medial-Golgi–restricted
localization of CDC42R186C was observed in the totality of COS-
1 cells ectopically expressing the mutant protein (Fig. 3 A). On
the other hand, a similar Golgi-specific targeting was not
observed for a representative panel of previously identified
disease-associated CDC42 mutants (e.g., p.Y23C, p.R68Q,
p.S83P, p.A159V, and p.E171K; Martinelli et al., 2018), sup-
porting the unique consequence of the p.R186C change on
CDC42 subcellular distribution. This distinctive localization
was observed in a disease-relevant cellular model, the YTS NK
cell line, generated by CRISPR/Cas9 technology to express the
mutant allele in the homozygous state (Fig. 3 B). Consistent
with these findings, an enriched Golgi localization was also
observed in the heterozygous primary fibroblasts obtained
from Pt 1 (Fig. 3 C).
We investigated the consequences of altered CDC42 locali-
zation and function on major cellular processes controlled by
CDC42, including proliferation, polarized migration, and cyto-
skeletal rearrangement. In vitro proliferation of CD34+ cells
from Pt 1 assessed in response to KIT ligand (KITLG) or a growth
factor mixture (KITLG, FLT3L, thrombopoietin, and IL3) re-
vealed a specific unresponsiveness to KITLG, suggesting a se-
lective hematopoietic proliferation signaling defect (Fig. 4 A).
Defective proliferation was also observed in fibroblasts derived
from Pt 1 and Pt 2, and NIH-3T3 cells transiently transfected to
overexpress the CDC42 mutant (Fig. 4 B). Notably, Pt 1 fibro-
blasts and NIH-3T3 cells overexpressing the mutant protein also
showed reduced polarized migration (Fig. 4 C). Consistently,
defective chemotaxis toward C-X-C motif chemokine 12
(CXCL12) was observed in Pt 1 purified bone marrow (BM)
CD34+ cells, peripheral blood mononuclear cells (PBMCs), as
well as in the homozygous CDC42R186C YTS NK cell line (Fig. 4 C).
CDC42 is critical for cytoskeletal rearrangement primarily
through the formation of filopodia, an F-actin–based structure
contributing to cell adhesion, polarization, and migration
(Etienne-Manneville, 2004; Mattila and Lappalainen, 2008;
Jacquemet et al., 2015). Thus, imaging of filopodial pattern and
cell polarization was performed in serum-stimulated fibroblasts
from Pt 1. A higher number of cells with filopodia and an ab-
errantly polarized morphology compared with control cells was
observed. In particular, aberrant polarization consisted of mul-
tiple lateral F-actin flat protruding edges (multipolar cells), in
contrast with the front-rear canonical polarization (Fig. 4 D).
Interestingly, in a cytolytic immunological synapse model on
glass surface utilizing higher resolution imaging, a lower num-
ber of filopodia was detected in the mutant YTS cells, with a
higher proportion of these cells retracting when activated on
a CD18/28 surface (Fig. 4 E). Together, these data documented a
variable perturbation of diverse cell-specific processes mediated
by remodeling of the actin architecture, including cell polarity
and migration.
Figure 1. Clinical features of patients carrying the c.556C>T change (p.R186C) in CDC42, and biochemical profiling of the disease-causing mutant. (A)
Skin findings of the affected subjects. (B) CDC42 levels in Pt 1 (n = 3, normalized intensity relative to HDs; **, P < 0.01, unpaired t test) and Pt 2 (n = 2) primary
fibroblasts and HEK-293T cells (n = 2) expressing FLAG-tagged WT and mutant CDC42 or an empty vector (EV). (C) CDC42 domain organization indicating key
functional regions and locations of residues affected by disease-causing variants. The two CDC42 isoforms are shown. Isoform 1 is ubiquitously expressed,
while isoform 2 is brain restricted. The missense variants affecting E171 and R186 only affect isoform 1, while mutations affecting the other residues involve
both isoforms. (D) p.R186C does not affect CDC42 posttranslational processing. MS analysis of WT and R186C CDC42 proteins shows a strong peak at 24,539
daltons and 24,486 daltons, respectively, indicating that CDC42R186C is properly processed at the C-terminus. Da, daltons. (E) p.R186C does not affect CDC42
GTPase activity and nucleotide exchange behavior. GTPase activity and nucleotide exchange reaction in CDC42R186C (right) are compared withWT CDC42 (left).
kobs values (observed dissociation constant) are reported (bottom). Representative polarization curves are shown (n = 4–6). MW, molecular weight; SAK/L,
serine-alanine-lysine/leucine motif.
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HLH occurring in infants and young children is generally
associated with defects in immune regulation, including func-
tion of NK cells (Henter et al., 2007). We observed a slightly to
markedly reduced NK cell activity in Pt 2 and Pt 3 through
clinical assessments of immune cell function (Fig. 5 A). The
homozygous CDC42R186C YTS cell line was used as an immune
cell model to directly study the impact of the mutant on NK
cytotoxicity. Chromium release assay against MHC class
Figure 2. p.R186C affects CDC42 binding to RhoGDI, IQGAP1, and WASP. (A) Structure of CDC42 complexed with RhoGDI. Visualization of residues
affected in human disease (left). Arg186 has a unique localization within the hypervariable region. Arg186 is surrounded by Asp140, Thr142, Tyr144, and Glu163 of
RhoGDI (within 4 Å; right middle panel). p.R186C is predicted to disrupt the interaction between the hypervariable region of CDC42 and RhoGDI (right lower
panel). (B) Pull-down (PD) assays showing RhoGDI interaction of prenylated WT and mutant CDC42. Binding of GST-fused RhoGDI to CDC42 proteins was
analyzed by WB documenting defective CDC42R186C binding. A representative image is shown (n = 2). (C) SPR analysis of the RhoGDI–CDC42 interaction.
Immobilized GST-tagged RhoGDI was titrated with increasing concentrations of WT (red) and R186C (black) CDC42GG proteins. No binding for the mutant
protein was observed. RU, response unit (n = 1). (D) Representative WB visualizing pull-down of overexpressed FLAG-tagged WT and R186C CDC42 from COS-
7 cell lysates by GST-fused effector proteins IQGAP1, PAK1, and WASP. The same amount of cell lysate was used as a loading control (tCDC42). Bar charts
indicate the relative levels of GTP-bound WT and R186C CDC42 normalized to the levels of total CDC42. A strongly reduced and decreased binding of
CDC42R186C to IQGAP1 and WASP was documented, respectively (mean ± SD, n = 3 independent experiments; *, P < 0.05; ****, P < 0.0001, one-way ANOVA
with Sidak’s multiple comparison test). n.s., not significant; MW, molecular weight.
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Figure 3. p.R186C leads to aberrant subcellular localization of CDC42. (A) CDC42R186C shows a Golgi apparatus–restricted localization. Immunofluo-
rescence staining of FLAG-tagged CDC42 proteins (green) and GM130 (red), a marker of cis/medial-Golgi apparatus, in COS1 cells transiently transfected with
mock DNA (empty vector [EV]), WT CDC42, or mutant alleles carrying different disease-causing mutations (Y23C, R68Q, S83P, A159V, E171K, and R186C).
Composite colocalization images are shown in the right panels with nuclei in blue. At least 200 FLAG-tagged CDC42-expressing cells were analyzed for each
sample. Representative image of three independent repeats. Scale bar, 20 µm (applicable to all other images shown). (B) Subcellular localization of CDC42 in
YTS NK cell lines homozygous for the p.R186C mutation. CDC42R186C was found to be predominantly localized to the Golgi apparatus with reduced cytoplasmic
signal. CDC42 signal intensity within the Golgi apparatus was quantified using giantin as a Golgi-specific marker relative to the cytoplasm and presented as a
ratio. Representative images of three independent repeats are shown. The graph shows the mean + SD of three independent experiments with n = 38 cells for
WT and n = 35 cells for R186C; **, P ≤ 0.01, unpaired two-tailed t test. Scale bar, 10 µm (applicable to all images shown). (C) Immunofluorescence staining of
CDC42 (green), GM130 (red), and nuclei (blue) in primary fibroblasts expressing WT CDC42 (HD) or heterozygous for p.R186C (Pt 1). Visual composite co-
localization images are shown in the merge panels. Colocalization (orange/yellow overlay) of CDC42 and cis-Golgi is detected in mutant CDC42–expressing
cells. Images refer to representative pictures of three independent experiments. Using GM130 as a mask for cis/medial-Golgi, CDC42 fluorescence intensity was
quantified as the ratio of Golgi to whole-cell staining using ImageJ software (mean ± SD, n = 3; **, P < 0.01, unpaired two-tailed t test). Scale bar, 20 µm
(applicable to all images shown).
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Figure 4. p.R186C is associated with defects in proliferation, migration, and formation of actin-based structures. (A) Proliferation of BM CD34+ cells
from Pt 1 in response to stem cell factor (SCF/KITLG) or a cytokine mixture (MIX; n = 1). (B) Proliferation of primary fibroblasts from Pt 1 (n = 3) and Pt 2 (n = 3)
at indicated time points of culture, and NIH-3T3 cells transiently expressing WT or mutant CDC42 or an empty vector (EV). (C) Migration assays of primary
fibroblasts from Pt 1 (n = 3), transfected NIH-3T3 cells (n = 3; *, P < 0.05; **, P < 0.01; ****, P < 0.0001, two-way ANOVA with Sidak’s multiple comparisons),
purified BM CD34+ sorted cells (n = 1), PBMCs (n = 2), and a YTS CRISPR/Cas9-modified cell line (n = 3; ****, P < 0.0001, unpaired two-tailed t test; mean ± SEM
for CD34+/PBMCs and mean ± SD for NK cells, NIH-3T3 cell line, and primary fibroblasts). Migration was assayed using a wound-healing assay on primary
fibroblasts and transfected NIH-3T3 cells and directed migration toward chemoattractant CXCL12 in BM CD34+ cells, PBMCs, and YTS NK cells. Decreased
directed migration of all tested cell types was observed. FI, fold increase of migratory cells. (D) Cytoskeletal rearrangements of cells expressing CDC42R186C.
Multipolarization and filopodia in primary fibroblasts from Pt 1 (n = 3) compared with fibroblasts from an HD. Immunofluorescence staining of CDC42 (red),
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I–negative 721.221 target cells demonstrated reduced cytotoxic
function in the mutant cell line through a cell-intrinsic defect
(Fig. 5 B). The reduction in cytotoxic function was in part due to
a reduction in the ability to form conjugates with target cells
(Fig. 5 C) and impaired migration (Fig. 4 C). Consistent with the
observed altered filopodia structure and number, these find-
ings suggest that immune dysfunction in the patients is likely
linked to actin dysregulation (Sinai et al., 2010).
The unique behavior of the CDC42R186C mutant was also
validated in vivo. In Caenorhabditis elegans, CDC-42 controls a
number of developmental programs, including vulval develop-
ment (Reiner and Lundquist, 2018). Our previous studies
documented that CDC42 mutations differentially perturb vulval
induction and morphogenesis, with some amino acid changes
up-regulating multiple signaling pathways, including those
mediated by LET-60/rat sarcoma (RAS), and others behaving as
hypomorphic mutations on WSP-1/WASP-dependent signaling
(Martinelli et al., 2018). In particular, overexpression of WT cdc-
42 at early/mid larval stage 3 (L3) was shown to induce the
formation of a single protrusion at the site of the vulva (pro-
truding vulva [Pvl] phenotype) in a WSP-1–dependent manner.
Ectopic expression of the WT protein also elicited a low pene-
trant multivulva (Muv) phenotype and partially rescued the
vulvaless (Vul) phenotype of nematodes carrying a hypomor-
phic let-23/EGFR allele, demonstrating hyperactivation of signal
flow through LET-60 and the MAPK cascade. Compared with
WT CDC-42, the K186C (homologue of R186C) mutant induced a
less penetrant Pvl phenotype and less efficiently rescued the Vul
phenotype, indicating a hypomorphic effect of this mutation on
both LET-60/RAS and WSP-1/WASP signaling pathways (Fig. 6,
A and B; and Table S4).
Collectively, the in vitro and in vivo biochemical and func-
tional data consistently indicate a unique impact of the identi-
fied disease-causing p.R186C change on CDC42 subcellular
F-actin (green), and nuclei (blue) in cells stimulated 3 h with 20% serum. In HD fibroblasts, CDC42 localizes to the front leading edge, whereas in Pt 1 fibroblasts,
the protein mostly localizes to the perinuclear area. On the right of the panel, quantification of multipolar cells and number of cells with short and long filopodia
length are shown. Cells bearing multiple F-actin flat protruding edges (butterfly shaped) were considered multipolar. While HD fibroblasts polarize showing a
front (leading edge), a large proportion of Pt 1 fibroblasts show multiple protruding edges. Filopodia twofold longer than nuclei diameter were considered long
filopodia. Filopodial length and number were notably increased in fibroblasts, suggesting a disruption of CDC42-dependent actin architecture. Scale bar, 20 µm
(applicable to all images shown). (E) Filopodia dynamics of the YTS cells on an activating CD18/CD28 surface. Filopodia were imaged using SIM-TIRF mi-
croscopy with representative images showing decreased filopodia count (mean ± SD, n = 3; **, P < 0.01, unpaired two-tailed t test with Welch’s correction) in
cells expressing CDC42R186C. Scale bar, 10 µm (applicable to all images shown). n.s., not significant.
Figure 5. p.R186C is associated with impaired NK cell cytotoxic function. (A) Assessment of NK cell cytotoxicity in Pt 2 and 3. Using NK cell cytotoxicity
assays, Pt 2 at diagnosis had a decreased cytotoxic function compared with an HD at the shown E/T ratios at time points 2 h and 3 h. For Pt 3 at diagnosis, NK
cells were stimulated with IL-2, and cytotoxicity was also decreased. (B) Functional characterization of YTS NK cell model. Standard Cr-51 release assay of YTS
NK cell lines against 721.221 target cells. The mutant cell line showed a significant decrease in cytotoxicity (pooled mean ± SD, n = 3 independent repeats each
with triplicates; ***, P < 0.001, Mann–Whitney U test). (C) Co-culture conjugation assay of YTS NK cell lines against 721.221 target cells. Compared with
parental YTS NK cells, a reduced ability of the YTS NK cells expressing the mutant allele to form conjugates with 721.221 target cells was also observed. A
representative figure is shown (n = 4).
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localization and function, which likely underlies the distinc-
tiveness of the trait.
Clinical profiling of NOCARH syndrome
The four unrelated patients sharing the same de novo missense
CDC42 mutation (p.R186C) showed a similar multisystem in-
flammatory disease characterized by pancytopenia, fever, skin
rash, hepatosplenomegaly, and persistently elevated inflamma-
tory markers. Differently from what had previously been re-
ported for other CDC42 mutations (Martinelli et al., 2018), no
neurodevelopmental involvement was observed. In these pa-
tients, Wiskott–Aldrich syndrome, idiopathic myelofibrosis,
dyskeratosis congenita, and classical immunodeficiency were
rapidly excluded based on established clinical, biochemical, and
genetic diagnostic criteria. Treatment with IL-1 inhibitors par-
tially improved fever and rash, and high chronic doses of glu-
cocorticoids were required to treat inflammation. Fatal HLH
developed in three cases.
Trilineage dyshematopoiesis was observed in BM with
prevalence of early differentiation elements, and decreased
clonogenic progenitor content having altered clonogenicity was
documented (Fig. 7 and Table S5). This indicates that the
p.R186C substitution in CDC42 affects hematopoiesis, ultimately
altering BM composition.
Since typical autoinflammatory features were present, we
investigated IL-1β production. Increased IL-1β secretion was
measured via ex vivo spontaneous IL-1β release from un-
stimulated BM mononuclear cells as well as high levels of IL-
1β in BM supernatants and plasma (Fig. 8, A and B). This finding
demonstrates that IL-1β overproduction is likely responsible for
part of the phenotype, particularly the observed features
typically associated with IL-1β–driven inflammasopathies
(i.e., fever, rash and elevated acute phase proteins; Harapas
et al., 2018). Remarkably, patients showed strikingly in-
creased production of IL-18. This was demonstrated by a 300-
fold higher ex vivo spontaneous IL-18 release from unstimulated
BM mononuclear cells and by levels of IL-18 in BM supernatant
and plasma that were ∼1,000-fold higher than those of healthy
donors (HDs; Fig. 8, A and B). Stimulation of BM mononuclear
cells with LPS or LPS plus ATP did not increase further IL-18
production as compared with unstimulated cells, suggesting the
presence of constitutive maximal activation of IL-18 processing
and release in the patient’s marrow. In contrast, no ex vivo
spontaneous IL-6 release from unstimulated BM mononuclear
cells was observed (Fig. 8 A), and circulating IL-6 levels in Pt
1 and Pt 2 were comparable to those observed in healthy subjects
(data not shown). Importantly, IL-18 is a potent costimulator of
IFN-γ production (Okamura et al., 1995), and IFN-γ appears to be
a common mediator of all forms of HLH (Grom et al., 2016).
Consistently, IFN-γ levels were increased in patients, particu-
larly during HLH episodes. In multiple samples available from Pt
1, we observed that elevated IFN-γ levels were strictly correlated
(r = 0.82) with elevated levels of CXCL9 (Fig. 8 C), a chemokine
specifically induced by IFN-γ that has been proposed as bio-
marker of HLH (Bracaglia et al., 2017). CXCL9 levels were strictly
correlated with levels of ferritin (r = 0.82), which is the most
typical marker of HLH activity. In line with the finding that IL-18
alone is not sufficient to induce IFN-γ, we did not find a signif-
icant correlation between IL-18 and IFN-γ or ferritin levels
(Fig. 8 C). Accordingly, in Pt 2, high IFN-γ levels were also
Figure 6. p.R186C affects C. elegans vulval development. (A) Hypomorphic effect of the mutation on pathways controlling C. elegans vulval development.
Compared with WT CDC-42, the K186C mutant induces a less penetrant Pvl phenotype and less efficiently rescues the Vul phenotype of animals carrying a
hypomorphic let-23/EGFR allele, indicating a hypomorphic behavior on multiple signaling pathways. The R68Q and A159V mutants, representative of group I
(substitutions characterized by impaired binding to regulators and effectors) and group II (gain-of-function changes) mutations, respectively, are shown for
comparison. Error bars indicate SEM of three independent experiments. Asterisks specify significant differences between animals expressing WT CDC-42 and
those expressing the empty vector (EV) or the let-23(sy1) allele (*, P < 0.05; ***, P < 1.2e-6; two-tailed Fisher’s exact test), and between animals expressingWT
and mutant CDC-42 (*, P < 0.05 [Muv] or P < 0.005 [Pvl and Vul]; **, P < 0.00002 [Pvl] or P < 3.2e-6 [Vul]). Number of animals are reported in Table S4.
(B) Representative images of C. elegans phenotypes. Scale bars, 20 µm.
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associated with high CXCL9 and ferritin levels (Table S1). In
addition, serum IL-6 levels were measured, and persistent
elevation was not detected (Fig. 8 A). Notably, in Pt 1, the
last severe HLH episode not responding to repeated gluco-
corticoid pulses, cyclosporine A, and high-dose anakinra
(10 mg/kg/d) was successfully treated with emapalumab, a
monoclonal antibody targeting IFN-γ. Altogether, these
data show that the R186C change in CDC42 leads eventually
to activation of the IFN-γ pathway through overproduction
of IL-18, which has been demonstrated to be associated with
secondary HLH development in the context of auto-
inflammatory diseases (Canna et al., 2014; Weiss et al.,
2018).
The surviving patient (Pt 1) underwent allogeneic HSCT from
his HLA-haploidentical father after selective depletion of αβ
T cells and CD19+ cells from the graft for preventing occurrence
of graft-versus-host disease and Epstein-barr virus–related
posttransplant lymphoproliferative disease, respectively
(Locatelli et al., 2017). The conditioning regimen used treosulfan,
thiotepa, and fludarabine. To avoid HLH flares, the patient was
given emapalumab and anakinra until days +28 and +100 after
HSCT, respectively. Neutrophil and platelet recovery occurred
on days +18 and +12 after HSCT; successful engraftment of donor
hematopoiesis was associatedwith normalization of IL-1β and IL-
18 production (Fig. 8 B). No inflammatory or HLH flare has been
observed up to day +210.
Figure 7. p.R186C leads to disruption of certain hematopoietic compartments. (A) Flow cytometric analysis of monocyte and dendritic cell (DC) im-
munophenotype on whole lysed peripheral blood of Pt 1 (n = 1) and Pt 2 (n = 1) showing a severe reduction of monocytes and myeloid dendritic cells. Upper
plots (Pt 1 and Pt 2) from left to right: after elimination of debris, we gated on CD14 or CD14, CD19, 7AAD SSClow cells to identify monocytes. In the CD14−
SSClow population, we gated on CD11c+ cells for dendritic cell identification in Pt 1. In the CD14−CD19−7AAD− SSClow population, we gated on CD1c, CD141, or
CD303 to distinct the dendritic cell major subtypes (MDC1, type 1 myeloid dendritic cell; MDC2, type 2 myeloid dendritic cell; PDC, plasmacytoid dendritic cell)
in Pt 2. Numbers within the plots show the frequency of monocytes and dendritic cells in the total events displayed. SSC-A, SSC-area; FSC-A, FSC-area. (B) The
ring chart shows absolute counts of distinct hematopoietic subpopulations on total CD45+ cells (indicated in the legend) in BM of pediatric HDs (n = 6) and Pt 1.
The stacked bar graph on the left is a zoom on the absolute count of hematopoietic stem and progenitor cell subtypes within the LIN−CD34+ compartment.
PreB/NK, B and NK cell progenitor; CMP, common myeloid progenitor; ETP, early T progenitor; GMP, granulocyte/monocyte progenitor; iPMN, immature
polymorphonucleated cell; MEP, megakaryocyte/erythrocyte progenitor; MLP multi-lymphoid progenitor; MPP, multi-potent progenitor; NKt, NK T cell; PMN,
polymorphonucleated cell.
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Discussion
Here, we characterize a previously unrecognized and dis-
tinctive hematological/autoinflammatory disorder due to a
specific missense mutation of CDC42 (p.R186C). By using
complementary biochemical and functional analyses, we
provide evidence that the disease-causing amino acid sub-
stitution has unique consequences on CDC42 function,
leading to a perturbation of hematopoiesis, immune func-
tion, and inflammatory response. We also provide a first
characterization of the clinical profile of the associated
phenotype and propose the acronym of NOCARH syndrome
to highlight the major features of the condition, including
neonatal onset of cytopenia, autoinflammation, rash, and
episodes of HLH.
Figure 8. p.R186C is associated with high
production of inflammasome-related cyto-
kines IL-1β and IL-18 in vivo and ex vivo. (A)
HD (n = 3) and Pt 1 BM mononuclear cells were
left unstimulated (US) or stimulated with LPS (10
µg/ml) for 5 h, with or without ATP (1 mM) for an
additional 1 h. Compared with unstimulated HD
cells, unstimulated Pt 1 cells release high levels
of IL-1β and IL-18. In LPS-primed HD cells, ATP
addition caused a marked increase in IL-1β and
IL-18 release, while this is not observed in LPS-
primed Pt 1 cells. IL-6 levels released in super-
natants were also measured; no spontaneous
release was observed. ND, not detectable. Se-
creted cytokines were measured by ELISA, and
results obtained were normalized by the abso-
lute number of monocytes per milliliter BM.
(B) IL-1β and IL-18 levels were measured in
plasma samples collected from Pt 1 and Pt 2 at
different time points over the course of the
disease. IL-1β and IL-18 levels were also mea-
sured in BM, and plasma samples were obtained
from Pt 1 30 d before and after HSCT. For HDs,
plasma n= 24 and BM n= 5. For Pt 1 and Pt 2, n= 1.
Mean ± SD is indicated. (C) Plasma levels of IFN-γ,
CXCL9, and IL-18 were measured in Pt 1 (squares)
and Pt 2 (triangles) and correlated with ferritin
levels, a typical marker of HLH activity. IFN-γ and
CXCL9 levels, but not IL-18 levels, are significantly
correlated with ferritin levels. Red squares and
triangles indicate samples collected when Pt 1 and
Pt 2 fulfilled at least five criteria required for HLH
diagnosis.
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CDC42 codes for a small GTPase of the Rho family controlling
multiple signaling pathways regulating cell polarity and migra-
tion, endocytosis, and cell cycle progression by cycling between
an active (GTP-bound) and an inactive (GDP-bound) state
(Etienne-Manneville and Hall, 2002; Etienne-Manneville,
2004). Recently, a number of missense mutations in this gene
have been associated with developmental traits characterized by
an unusually broad spectrum of anomalies, with core clinical
features including defective growth, intellectual disability, brain
malformations, facial dysmorphism, hearing/vision problems,
cardiac malformations, and immune and hematologic and lym-
phatic defects (Takenouchi et al., 2015; Martinelli et al., 2018).
Genotype–phenotype correlations were identified and linked to
a variable functional impact of mutations, suggesting specific
consequences of individual mutations on cellular processes
controlling development. In contrast to those phenotypes, NOCARH
syndrome is a hematological and autoinflammatory condition with
no major involvement of other systems, which is in line with the
documented peculiar functional consequences of the p.R186C
change on protein function.
Our immunophenotype and clonogenic data are consistent
with previous findings showing that controlled inactivation of
CDC42 in BM cells results in altered frequency and distribution
of hematopoietic stem cells, decreased abundance of long-term
hematopoietic stem cells, and occurrence of myeloid and ery-
throid developmental defects, as well as functional defects in
engraftment, migration, and BM retention (Yang et al., 2007a,b).
Notably, present findings confirm the key role of the GTPase in
controlling processes implicated in hematopoietic stem and
progenitor cell fate and behavior.
Based on structural modeling and biochemical and cellular
testing, we predicted and confirmed the mutated protein to have
impaired interaction with known regulators and effectors, in-
cluding RhoGDI, IQGAP1, and WASP, leading to aberrant sub-
cellular localization, actin cytoskeleton rearrangement, and
reduced migration. CDC42 mislocalization data are consistent
with the physiological role played by RhoGDI and IQGAP1, key
mediators of membrane cycling of CDC42 (Gibson and Wilson-
Delfosse, 2001; Swart-Mataraza et al., 2002; Gibson et al., 2004).
The observation that cells expressing the p.R186C variant un-
dergo deep cytoskeletal rearrangements leading to multiple
leading edges is congruous to findings by Fukata et al. (2002)
showing that cells expressing IQGAP1 mutants defective in
CDC42 binding display aberrant multipolar morphology. This
supports the notion that the IQGAP1–CDC42 interaction is cru-
cial to cell polarization and migration. Notably, the finding that
CDC42 aberrant localization and trafficking is coupled to altered
polarization and migration is in line with the relevant role
played by CDC42 at the Golgi and the leading edge in the control
of cell polarity (Baschieri et al., 2014). Compositional and func-
tional assessment revealed impaired proliferation and polarized
migration, further emphasizing the requirement of proper
CDC42 function in these processes (Martinelli et al., 2018). No-
tably, although we were unable to identify a specific CDC42
functional perturbation associated with the p.R186C change as
causally linked to the complex phenotype of NOCARH syn-
drome, this mutant seems unique in its mislocalization, which
suggests this is a key factor in the pathogenesis for this uniquely
presenting disease.
Our findings indicate that aberrant CDC42 function can in-
volve components of hyperinflammation and immune impair-
ment in NK cells, contributing to the HLH phenotype observed
in NOCARH. The underlying pathogenetic mechanism of the
p.R186C mutation in the context of anemia and thrombocyto-
penia has yet to be determined, suggesting a context-dependent
effect on specific blood cell compartments. Future studies in-
volving murine models carrying the heterozygous mutation
would be needed to assess the effect on hematopoiesis in a
similar context to that of our patients.
Several mutations in genes with a role in actin cytoskeleton
remodeling of immune cells have been demonstrated to be in-
volved in the pathogenesis of hematological/autoinflammatory
diseases, underlining the importance of the actin cytoskeleton in
modulating inflammatory responses. Indeed, mutations in the
actin-binding protein cofilin (CFL1; Seeland et al., 2018), WAS
(Li et al., 2017), DOCK8 (Dasouki et al., 2011), and ARPC1B
(Brigida et al., 2018), as well as in RAC2, a Rho GTPase struc-
turally and functionally related to CDC42 (Caye et al., 2015; Hsu
et al., 2019), cause abnormal migration, proliferation, and/or
differentiation of lymphoid and/or myeloid cells and are asso-
ciated with features of autoinflammation. Moreover, aberrant
actin depolymerization due to an inactivating mutation of the
actin-depolymerizing cofactor Wdr1 has been demonstrated to
cause in mice an autoinflammatory disease characterized by
spontaneous autoinflammation, thrombocytopenia, and neu-
trophilia (Kim et al., 2015). In these mice, the autoinflammatory
phenotype is IL-18, but not IL-1β, dependent and is driven by
activation of the pyrin inflammasome. In our study, we could
not investigate the exact molecular mechanism involved in the
overproduction of IL-18 and the role of CDC42 in inflammasome
regulation. However, the spontaneous release of IL-18 by BM
mononuclear cells, associated with high IL-18 circulating levels,
has been exclusively described in patients carrying mutations in
the NLRC4 protein (Canna et al., 2014) who present with re-
current episodes of HLH. Moreover, it is well known that in-
activation of RhoA GTPases by many bacterial toxins is sensed
by the inflammasome (Jamilloux et al., 2018). Interestingly,
IQGAP1 has also been described as a novel regulator of caspase-
1 in macrophages infected with Yersinia pestis (Chung et al.,
2014). Based on the above-mentioned observations regarding
the connection between the actin cytoskeleton and inflamma-
tion, we propose the term “inflammatory actinopathies” to
group these diseases, including NOCARH, differently from ac-
tinopathies with neurological and myologic features.
In conclusion, NOCARH is an autoinflammatory disease at
high risk for HLH, similarly to what has been observed for the
disorder caused by NLRC4 gain-of-function mutations (Canna
et al., 2014; Romberg et al., 2014). Given the observed auto-
inflammation associatedwithmarkedly elevated IL-18 levels, the
mechanism is most likely associated with the role of IL-18 as a
costimulus for IFN-γ production. The characteristic inflamma-
tion in two patients in conjunction with elevated IL-18 levels
support IL-18 as a disease biomarker for diagnosing NOCARH
and potentially related syndromes of dysregulated CDC42
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function that involve inflammation. One patient survived se-
vere HLH, and this appears to have been dependent on timely
therapeutic neutralization of IL-1 and IFN-γ. Early recognition
and establishment of treatment for NOCARH, based on the
unique association of early-onset trilinear cytopenia and au-
toinflammation, are crucial to prevent multiorgan failure and
subsequent death.
Materials and methods
Detailed clinical history of patients
Pt 1
Pt 1 is a 6-yr-old Caucasian girl born from healthy unrelated
parents with no family history of genetic disease. At birth, she
presented with persistent high fever; erythematous skin lesions
of the face, trunk, and limbs; a large abdomen because of he-
patosplenomegaly (spleen diameter, 6.4 cm); and suspected
trigonocephaly (Table 1). Laboratory tests showed an increase in
inflammatory markers and a severe trilinear cytopenia requir-
ing frequent red blood cell and platelet transfusions during the
first year of life. BM biopsy at disease onset revealed fibrosis
with trilineage dyshematopoiesis (prevalence of early differen-
tiation elements in erythroid and myeloid lineage, dysmorphic
and reduced megakaryocytes, increased lymphocytes, and
abundant CD68+ histiocytes with focal or absent phagocytosis;
Tables S1 and S2). Given the partial clinical overlap with chronic
infantile neurological cutaneous articular syndrome–neonatal-
onset multisystem inflammatory disease (CINCA-NOMID), she
was started on glucocorticoids and daily therapy with anakinra,
with improvement of fever and rash, but no effect on cytopenia.
Failure to thrive was present. Treatment with G-CSF was started
with partial response. Recurrence of inflammatory symptoms
following tapering and/or discontinuation of glucocorticoids
was observed. At age of 11 mo, she presented with recurrent
episodes of intestinal bleeding, associated with persistent/
chronic diarrhea. Meckel’s diverticulum was excluded. At 2 yr
and 6 mo, she presented with three episodes of generalized
seizures followed by hypotonia, hypersomnia, and transient
hemiparesis requiring in one case admission to an intensive care
unit. Magnetic resonance imaging (MRI) performed during the
first episode showed lesions suggestive of inflammatory central
nervous system involvement; during the third episode, the MRI
showed one additional lesion of the brainstem. CSF was sterile,
CSF white blood cells were 18/mmc, and no hemophagocytic
cells were detected. All the episodes were treated with a high
dose of i.v. glucocorticoid with good response; therapy with
levetiracetam was started. At the age of 5 yr, because of in-
complete control of the inflammatory state, anakinra was
switched to canakinumab. Starting from 5 yr of age, she devel-
oped four episodes of full-blown HLH, fulfilling the HLH-2004
diagnostic criteria. All episodes were treated with high dose of
i.v. glucocorticoids and cyclosporine-A with resolution in all
cases except one. The last episode was severe and associated
with massive intestinal ischemia and necrosis requiring surgical
resection and consequent ileocolostomy. This episode was un-
responsive to high-dose glucocorticoids and IL-1 inhibition.
Treatment with emapalumab, an anti–IFN-γ antibody, was
added with rapid resolution of the episode. At age of 6 yr, the
patient underwent allogeneic HSCT from her HLA-
haploidentical father after a selective depletion of αβ T cells
and CD19+ cells from the graft. The conditioning regimen con-
sisted of a combination of treosulfan, thiotepa, and fludarabine.
To avoid flares of HLH, the patient was given emapalumab and
anakinra until days +28 and +100 after the allograft, respec-
tively. Neutrophil and platelet recovery occurred on days +18
and +12 after HSCT. Normalization of the acute phase response
and no inflammatory or HLH flare have been observed up to
day +210.
Pt 2
Pt 2 was a male born from Caucasian healthy unrelated parents.
Since the first day of life, he presented with persistent fever,
skin rash, mild hepatosplenomegaly, failure to thrive, increase
in inflammatory markers, and trilinear pancytopenia that re-
quired red blood cell and platelet transfusions. Extensive mi-
crobiological screening revealed a positive IgM titer for
parvovirus B19, with B19 parvovirus PCR negative on whole
blood. At age 57 d, he was first seen at one of our centers
transferred from another hospital. He presented with failure to
thrive (height and weight below the fifth percentile), persistent
fever, skin rash, mild hepatosplenomegaly, and chronic diarrhea
and positive blood stool. Inflammatory bowel disease was sus-
pected, and temporary parenteral nutrition started. Laboratory
tests showed elevated acute-phase reactants and severe trilinear
cytopenia requiring recurrent red blood cells and platelet
transfusions. BM biopsy revealed dyshematopoiesis and some
lymphohistiocytic aggregates without significant hemophago-
cytosis. The disease course was characterized by a persistent
inflammatory state despite several treatment attempts with
glucocorticoids, antibiotics, high doses of i.v. immunoglobulins,
and cyclosporine-A. Suspecting an autoinflammatory condition,
treatment with anakinra was also started with only partial im-
provement of the clinical and laboratory parameters. At age 7
mo, he developed severe HLH with multiorgan failure that
rapidly progressed to death. Extensive immunological workup
showed severe monocytopenia and reduction of plasmacytoid,
myeloid dendritic cells, neutropenia, increased central memory
CD4+ cells with reduced naive and recent thymic emigrant CD31+
cells, increased regulatory T cells with high memory phenotype,
and increased switched B cell memory cells, plasma cells, and
autoreactive B cells associated with reduced transitional B cells
(Table S2).
Pt 3
Pt 3 was a female born from nonconsanguineous Caucasian
parents with no family history of inherited diseases. At birth,
she presented with generalized rash, intermittent cytopenia
(leukopenia, thrombocytopenia, and anemia requiring trans-
fusions), and generalized lymphadenopathy. Hepatospleno-
megaly, nutritional problems, and stagnant growth were also
noted within the first few months after birth. The anemia was
profound and required several red blood cell transfusions. At age
3 mo, the condition was thought to be CINCA-NOMID, and
treatment with anakinra was started, which was temporarily
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effective for rash and overall inflammation, but not cytopenia.
Treatment was stopped due to respiratory infections and no
clear effect of the treatment. 6 mo later, she started treatment
per modified HLH-2004 protocol with steroids and weekly
etoposide-phosphate over 8 wk. No neurological deficits were
noted, but the patient declined over time, requiring increasing
erythrocyte and thrombocyte transfusions. She was then
transferred to another hospital, and for the first few weeks, she
was stable, but she developed signs of an HLH relapse with
increased hepatosplenomegaly, high ferritin, high trigly-
cerides, bicytopenia, and a florid rash. Histologically, hemo-
phagocytosis was not detected. She also developed breathing
difficulties of unknown origin. She was commenced on a
modified HLH-2004 protocol with the addition of antithymo-
cyte globulin, infliximab, and anakinra. There was some clin-
ical response on this treatment and a decision to opt for a stem
cell transplant was made. While she was being investigated and
prepared for transplant, she continuously deteriorated; she was
treated with two courses of alemtuzumab in this time period.
She received a CD3/CD19-depleted haploidentical transplant
and died 4 d later.
Pt 4
Pt 4 was a boy born in week 34 to nonconsanguineous parents
from a Christian minority originating from the Middle East with
a history of thalassemiaminor and familial cardiomyopathy. The
patient was small for gestational age and presented at birth with
bloody diarrhea, cholestasis, ascites, and a generalized rash. He
had an unusually small thymus for his age. The patient also
rapidly developed additional symptoms, including stiff/con-
tracted joints, high fever, highly elevated inflammatory mark-
ers, intermittent cytopenia (thrombocytopenia and anemia
requiring transfusions), hepatomegaly, and diatheses (bleeding
from the mucosas; Table 1). At 2 wk of age, an extensive workup
was initiated. Investigations excluded known gut, liver, and
metabolic diseases. Immunological investigations slightly low-
ered number of T cells with prevalence of naive T cells. Results
of functional tests of NK/T cells and degranulation ability were
normal. Serum IL-6 and IL-18 was remarkably high on repeated
occasions. An autoinflammatory condition in combination with
a primary immunodeficiency was suspected. The patient was
treated with high dose glucocorticoids and anakinra. Because of
insufficient response tocilizumab was also added. This intensive
antiinflammatory treatment was effective for some of the rash,
ascites, cholestasis, as well as intermittently for overall inflam-
mation and cytopenia. The patient needed supportive treatment
in the intensive care unit on six separate occasions, four of
which were due to macrophage activation syndrome–HLH epi-
sodes, likely triggered by infection.
Severe gastrointestinal symptoms and unexplained mucosal
bleedings persisted. The patient continued to have watery di-
arrhea. Gastroduodenal endoscopy showed severe inflammation
with ongoing bleeding. Biopsies of the duodenum showed acute
and chronic inflammation with ulcers. In connection with co-
lonoscopy, the patient suffered a perforation and needed sur-
gery. Since no matched related SCT donor was available, a
search for an unrelated matched donor was initiated; however,
his conditions were too unstable with no signs of remission, and
HSCT was considered too risky. Because of the symptoms of
agonizing pain and high levels of anxiety, and in the presence of
no response to treatments, the antiinflammatory therapies were
gradually stopped, and the patient was transferred to another
hospital for palliative care, where he died at 4.5 mo of age.
Mutation analyses
This study was approved by the Ospedale Pediatrico Bambino
Gesù and Baylor College of Medicine Ethical Committees. Clin-
ical data and DNA specimens from the subjects included in the
study were collected following procedures in accordance with
the ethical standards of the declaration of Helsinki protocols and
approved by the review boards of all involved institutions, with
signed informed consents from the participating subjects/fam-
ilies (study protocol for Pt 1 and 3: “Genome Sequencing to
Elucidate the Causes and Mechanisms of Mendelian Genetic
Disorders” [H-29697] of Baylor College of Medicine; study pro-
tocol for Pt 1 and 2: 1702_OPBG_2018).
Pt 1
Exome capture was performed using SureSelect AllExon
v5+UTR (Agilent) and sequenced on a HiSeq platform (Illumina).
WES data were processed and analyzed using an in-house–
implemented pipeline as previously described (Flex et al., 2016;
Stray-Pedersen et al., 2017; Bauer et al., 2018). Briefly, reads were
aligned to human genome build GRCh37/UCSC hg19, and variants
were quality filtered according to the Genome Analysis Toolkit’s
2016 best practices, annotated, and filtered against public
(dbSNP150 and gnomAD V.2.0.1) and in-house (>1,300 population-
matched exomes) databases to retain private and rare (unknown
frequency or minor allele frequency <0.1%) variants located in
exons with any effect on the coding sequence (CDS) and within
splice site regions. Functional annotation of variants was performed
using SnpEff v.4.3 and dbNSFP V.2.9, and functional impact was
analyzed by CADD v.1.3 andM-CAP v.1.0.(Cingolani et al., 2012; Liu
et al., 2013; Kircher et al., 2014; Jagadeesh et al., 2016). Average
coverage was 91× and 20× for ≥86% of the target. Among
127,405 high-quality variants, 14,224 affect either the CDS or splice
sites, while 338 have low or unknown frequencies according to the
aforementioned frequency thresholds. For sequencing statistics, see
Table S3. Relevant variants and the de novo origin of the c.556C>T
change were validated by Sanger sequencing.
Pt 2
Mutation analysis was performed by Sanger sequencing using
DNA obtained from circulating leukocytes. Primer pairs are
available upon request.
Pt 3
Initial mutation analysis was performed by Sanger sequencing
(and Baylor College of Medicine CMA v9.1), which was negative
for NLRP3, IL1RN, LPIN2, NOD2, MEFV, TNFRSF1A, PSTPIP1, MVK,
and PSMB8. The patient was identified in a shared CMG database
at Baylor College of Medicine by searching for rare, likely
damaging variants (using the Exome Aggregation Consortium
and CADD) in CDC42 in a cohort of unsolved immunodeficiency
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probands. On further study, patient had underwent trio-based
WES in Norway, revealing the presence of the de novo c.556C>T
change in CDC42, and proband-only WES was repeated at Baylor
College of Medicine. Sanger sequencing of proband and parents
was then performed, confirming the presence of a de novo
variant (Table S3).
Pt 4
Blood samples from the patient and his parents were obtained
with informed consent according to the Declaration of Helsinki.
The study was approved by the Regional Ethics Review Board in
Stockholm, Sweden. DNA samples were subjected to trio-based
WGS with a TruSeq DNA PCR-free protocol followed by se-
quencing on an Illumina HiSeq X machine with an average
coverage of 34×. Sequencing reads were analyzed with the
pipeline SpeedSeq. In brief, reads were mapped to the human
genome build GRCh37 with Burrows–Wheeler aligner, while
calling of single-nucleotide and structural variants was per-
formed, respectively, with FreeBayes and Lumpy. No mutations
were identified in HLH/autoinflammation–related genes. The
genomic region spanning CDC42 was visualized with the Inte-
grative Genomics Viewer, indicating a de novo c.556C>T muta-
tion, which was validated by Sanger sequencing (Table S3).
MS
WT CDC42 from TNAO38 insect cells were dissolved in 50%
(vol/vol) acetonitrile and 0.2% (vol/vol) formic acid at a final
concentration of 2 mg/ml. Proteins were subjected to a C4 HPLC
column (MassPrep Online Desalting Cartridge, dimensions 2.1 ×
10 mm; Waters) equilibrated with 20% (vol/vol) acetonitrile and
0.1% (vol/vol) formic acid. For HPLC separation, the following
conditions were used: HPLC-system U300 series (Agilent
Technology), a flow rate of 500 µl/min; eluent A, 0.1% (vol/vol)
formic acid in water; eluent B, 0.1% (vol/vol) formic acid in
acetonitrile; gradient conditions, 20% B for 0.5 min, linear
gradient up to 60% B in 1.5 min, linear gradient up to 90% B in
0.5 min, 90% B for 0.5 min, and reequilibration of the column.
The HPLC system was coupled on-line to an ion trap mass
spectrometer (VelosPro; ThermoFisher Scientific) equipped
with an electrospray ionization source. Full spectra were ac-
quired using a mass-to-charge range of 700–2,000. Obtained
spectra were deconvoluted using the program package Promass
(ThermoFisher Scientific). Masses obtained from the respective
spectra are described with respect to calculated molecular
weights (CH3, methyl group; Ic, insect cells; GG, geranylgeranyl
moiety).
Constructs and proteins for biochemical analysis
pGEX vectors were used for bacterial overexpression of
CDC42WT, CDC42R186C, RhoGDI-1, p50GAP, ITSN1, WASP
(GTPase-binding domain), PAK1 (GTPase-binding domain), and
IQGAP1 (863–1,657). All proteins were isolated as GST fusion
proteins in Escherichia coli BL21 (DE3) purified after cleavage of
the GST tag via gel filtration (Superdex 75 or 200; Pharmacia).
Nucleotide-free and fluorescent nucleotide-bound CDC42 were
prepared using alkaline phosphatase (Roche) and phosphodies-
terase (Sigma-Aldrich) at 4°C as described. Fluorescent nucleotide
was methylanthraniloyl (mant-) GppNHp (guanosine 59-
β,γ-imidotriphosphate), a nonhydrolysable GTP analogue. All
proteins were analyzed by SDS-PAGE and stored at −80°C. The
GTPase assay and nucleotide exchange reaction were performed
with a Hi-Tech Scientific (SF-61) stopped-flow instrument. The
release of fluorescently labeled GDP (mantGDP) was measured
basally and with the catalytic GEF domain of ITSN1. Hydrolysis
of tamraGTP was measured basally and following stimulation
with the catalytic GAP domain of ARHGAP1 (p50GAP). The ex-
citationwavelengths were 543 nm and 362 nm for tamraGTP and
mantGDP, respectively. Fluorescence experiments were per-
formed in a Fluoromax 4 fluorimeter in polarization mode. Hu-
man WT and mutant CDC42 were subcloned into pFastBacHTB
vector (Invitrogen) and fused with an N-terminal hexa-histidine
(6xHis) tag and transformed into DH10BAC strain for insect cell
purification.
Fluorescence assays
The GTPase assay and nucleotide exchange reaction were per-
formed with a Hi-Tech Scientific (SF-61) stopped-flow instru-
ment. The excitation wavelengths were 543 nm and 362 nm for
tamraGTP (Jena Bioscience) and mantGDP (Jena Bioscience),
respectively. For the GTPase assay, equal volumes (600 µl) of
0.2 µM CDC42-tamraGTP and 10 µM of p50GAP in 30 mM Tris/
HCl, pH 7.5, 10 mM K2HPO4/KH2PO4, 5 mM MgCl2, and 3 mM
dithiothreitol at 25°C were rapidly mixed and transferred to a
fluorescence detection cell within seconds. For the nucleotide
exchange reaction, 0.2 µM CDC42-mantGDP and 40 µM GDP +
10 µM ITSN1 were used.
Structural analysis
To elucidate the impact of substituted arginine to cysteine at
residue 186, the protein–protein interaction between CDC42 and
RhoGDI-1 (PDB: 1DOA) was analyzed. Residues in vicinity ≤4 Å
were considered as part of binding interface of Arg186. Analysis
and illustrations were made using the PyMOLmolecular viewer.
SPR
A Biacore X100 instrument (GE Healthcare) was used in a single-
cycle mode to analyze the kinetics of interaction betweenWT or
R186C CDC42GG with RhoGDI. SPR experiments were performed
at 25°C in HBS-P+ running buffer (10 mMHEPES pH 7.4, 0.15 M
NaCl, 0.05% [vol/vol] surfactant P20; GE Healthcare). GST
capturing method was used to immobilized GST antibody on the
surface of CM5 chip. 4 µM GST-GDI (5 µl/min) in HBS-P buffer
injects for the period of 180 s in order to immobilized GST-GDI
over the chip surface. Regeneration of the chip performed using
10 mM glycine, pH 3.0, at the end of each experiment. WT and
R186C CDC42GG were injected in 0.06–1 µM concentrations with
twofold increase in each injection step. Final curve was fitted in
a 1:1 binding model.
Cell lines and cultures
Dermal mutant fibroblasts were obtained from patients, and
HEK-293T, COS-1, and NIH-3T3 cell lines and primary control
dermal fibroblasts were obtained from American Type Culture
Collection and grown in high-glucose DMEM supplemented
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with 10% FCS, 2 mM L-glutamine, and 10 U/ml penicillin/
streptomycin (all from Sigma-Aldrich). YTS cells, a subclone of
the YT cell line, were cultured in R10 composed of RPMI-1640
supplemented with 10% FBS (Premium; Atlanta Biologicals),
2 mM L-glutamine (ThermoFisher Scientific), 1 mM sodium
pyruvate (ThermoFisher Scientific), 1% MEM nonessential
amino acid (100×; ThermoFisher Scientific), 10 mM Hepes
(ThermoFisher Scientific), and 1% penicillin/streptomycin (Ther-
moFisher Scientific).
Plasmids for CDC42 expression in HEK-293T, COS-1, and
NIH-3T3 cell lines
WT human CDC42 isoform 1 (NP_001782.1) was cloned into a
pcDNA3-FLAG backbone using PCR and standard cloning
methods via BamHI and EcoRI digestion. Mutant constructs
carrying the R186C change were generated by site-directed
mutagenesis using the QuikChange XL kit (Agilent Technolo-
gies) and verified by direct sequencing. Each of the FLAG-tagged
CDC42 protein expression constructs or the empty vector was
transfected using Fugene 6 (Roche). 24 h after transfection, cells
were assayed for cell growth or processed for wound healing
assays, immunofluorescence, or immunoprecipitation analysis.
Transfection efficiency was verified by Western blot (WB)
analysis of the protein lysate.
Pull-down of CDC42 variants from COS-7 cell lysates
COS-7 cells were transfected with pcDNA3.1-Flag plasmids
containing WT and R186C CDC42 and transiently overexpressed
for 48 h. 10 µg of each plasmid was used for transfection of the
COS-7 cells (900,000 cells per 10-cm Petri dish). Empty vector
was used as control. 20 µl TurboFect transfection reagent
(ThermoFisher Scientific) was added to the plasmids and incu-
bated for 20 min at room temperature before adding it to the
cells. Medium was changed after 4 h, and cells were incubated
for 48 h. Cells were lysed in an ice-cold buffer containing 50mM
Tris/HCl, pH 7.4, 100 mM NaCl, 2 mMMgCl2, 1% Igepal Ca-630,
10% glycerol, 20 mM β-glycerolphosphate, 1 mM Na3VO4, and
one tablet EDTA-free protease inhibitor (Roche). Cell lysates
were incubated with glutathione beads coupled to GST-effector
proteins for 30min at 4°C. Beads werewashed five times, heated
in 1× Laemmli buffer at 95°C for 10 min, and subjected to SDS-
PAGE for immunoblot analysis. WB was performed using an
anti-FLAG antibody (F3165, M2; Sigma-Aldrich) and anti-
GAPDH antibody (21185, clone 14C10; Cell Signaling
Technology).
Polarized migration
Polarized migration of primary fibroblasts and NIH-3T3 cells on
fibronectin-coated wells (10 μg/ml; Sigma-Aldrich) were eval-
uated by wound-healing assays. Monolayers of cells were
scratched with a 200-µl micropipette tip and incubated in low-
serum medium (2% FBS in DMEM high glucose without Phenol
red, 2 mM L-glutamine, and 1% penicillin/streptomycin; all
purchased from Sigma-Aldrich) in the presence of thymidine (10
mM, T1895; Sigma-Aldrich) to inhibit cell proliferation. Images
were acquired at different time points using a Nikon Eclipse
TS100 microscope, a Nikon Plan Fluor 10×/0.13 objective, and a
Nikon Coolpix 990 digital camera. Cells that had migrated in the
wounded area were counted in four fields per well, and the fold
increase of migratory cells was evaluated after scratch at the
time points indicated.
Proliferation and viability
Proliferation and viability of transiently transfected NIH-3T3
cells and primary fibroblasts were quantified by manual
counting using a Neubauer hemocytometer. Cell viability was
detected by the exclusion of trypan blue dye (5 mg/ml in PBS,
ECB4004L; Euroclone). Cells were counted at different time
points by phase contrast using a Leitz Ortholux II microscope
and a Leitz 10×/0.13 objective.
Immunofluorescence analysis of primary fibroblasts and
COS-1 cells
Cells were washed in PBS, fixed (4% paraformaldehyde [PFA],
20 min, room temperature), washed twice, treated for free
aldehydes quenching (50 mM NH4Cl, 10 min at room tem-
perature), and washed again. After 5-min permeabilization
with 0.5% Triton X-100 in PBS, cells were blocked for 30 min
with 2% FBS and 1% BSA in PBS. Then, cells were sequentially
incubated with primary and secondary antibodies 1.5 h at
37°C, 1:500 mouse anti-FLAG (F-1804; Sigma-Aldrich) or 1:50
mouse anti-CDC42 (SC8401; Santa Cruz); 30 min at room
temperature, 1:100 goat anti mouse Alexa Fluor 488 (A11017;
ThermoFisher Scientific); 30 min room temperature, 1:50
rabbit anti-GM130 (PA1-077; ThermoFisher Scientific); and
30 min at room temperature, 1:100 goat anti-rabbit Alexa
Fluor 568 (A11011; ThermoFisher Scientific). All antibodies
were diluted in 0.5% BSA and 0.1% saponin in PBS. Unbound
antibodies were removed after each incubation by three
washes with washing buffer (0.2% BSA in PBS). After a 30-
min incubation with phalloidin-Alexa Fluor 647 (Life Tech-
nologies), coverslips were washed and then mounted on glass
slides with 5 µg/ml Hoechst33342 (Life Technologies) nuclear
dye in antifade reagent (ThermoFisher Scientific) and ana-
lyzed. Imaging was performed on an Olympus FV1000 using
excitation spectral laser lines at 405, 488, and 633 nm. Signals
from different fluorescent probes were taken in sequential
scanning mode. Images were captured using Olympus Fluo-
View Viewer Software. Golgi localization of CDC42 in primary
fibroblasts was quantitated using GM130 as a mask for cis/
medial-Golgi, and CDC42 fluorescence intensity was quanti-
fied as the ratio of Golgi to whole-cell staining by using ImageJ
software. Multipolar and filopodia-bearing cells were deter-
mined (blinded to sample information) by manually counting
in FluoView Viewer ≥200 cells from ≥10 randomly chosen
images. Cells having multiple F-actin flat protruding edges
(butterfly shaped) were considered multipolar, while cells
showing a front (leading edge) and a rear were considered
unipolar. To calculate the average filopodial length, the dis-
tance from the cell base to the tip was determined. Actin
protrusions <1 µm were not considered as filopodia. Filopodia
measured as twofold longer than nuclei diameter were con-
sidered long filopodia, while the remaining filopodia were
considered short.
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CRISPR cell line production
The immortalized YTS humanNK cell linewas used as themodel
for immune function. In collaboration with the Cell Based Assay
Screening Service at Baylor College of Medicine, a homozygous
knock-in of the c.556C>T/p.R186C mutation was placed into
chromosome 1, isoform 1 of CDC42. Briefly, guide RNAs were
screened in 293T cells for editing efficiency. Each guide RNA
was incorporated into an all-in-one vector encoding Cas9
and eGFP.




synthesized incorporating the desired mutation, a silent muta-
tion encoding for the SbfI restriction site, and another mutation
to reduce Cas9 recutting. Constructs were transfected into the
parental YTS cell line (Neon electroporator, 1,400 V/10ms/three
pulses, 2.5e6 YTS cells). Cells were sorted based on eGFP 48 h
later and plated by limiting dilution. Clones were screened based
on genomic extraction and SbfI digestion and then sequenced
using Sanger sequencing of the targeted region for verification.
Clones were expanded in R10 medium and then underwent re-
peat Sanger sequencing for the presence of the CDC42 mutation
and for the lack of off-site mutagenesis at GBA3, a known
pseudogene of CDC42. A single clone was used for all YTS ex-
periments presented.
YTS fixed-cell immunofluorescence confocal microscopy
YTS cells were washed once with complete R10 and resuspended
to a final concentration of 1e6/ml in complete R10. 200,000 cells
were plated onto a poly-lysine–coated slide and incubated at
37°C for 20 min for adherence. After incubation, cells were
gently washed three times with PBS and fixed and permeabilized
with BD cytofix/cytoperm (554655; BD Biosciences) for 20 min
at room temperature. All subsequent washes and antibody in-
cubations are done with PBS-S (PBS + 1% BSA + 0.1% saponin).
Cells were incubated with anti-CDC42 (1:300, 187643; Abcam)
for 1 h at room temperature followed by goat anti-rabbit Alexa
Fluor 568 (1:300, A11011; ThermoFisher Scientific) for 1 h.
Lastly, cells were incubated with phalloidin-Alexa Fluor 647
(1:100, A22287; ThermoFisher Scientific) and anti-giantin
Alexa Fluor 488 (1:200, #908701/Poly19087; BioLegend) for
1 h. After washing, cells were mounted with Prolong Diamond
(P36970; ThermoFisher Scientific) to a #1.5 coverslip and al-
lowed to cure for 24 h before sealing with nail varnish. Imaging
was done using Metamorph on a Zeiss Axio Observer CSU-X
confocal microscope with a 63×/1.4 NA objective. Colocalization
was conducted in ImageJ software where a segmentation mask
was created around the Golgi apparatus (using giantin
thresholding) and cell membrane (using CDC42 thresholding)
and average intensity signal within the Golgi and the cytoplasm
were measured. The ratios between the signal within the Golgi
and the cytoplasm were calculated.
SIM-TIRF microscopy and filopodial analysis
A Lab-Tek II 8-well chambered #1.5 coverglass (#155409; Nunc)
was coated with 5 μg/ml anti-CD18 (IB4, single batch) and 5 μg/ml
anti-CD28.2 (LEAF anti-CD28.2, 302923; BioLegend) and incu-
bated for ≥30 min at 37°C. YTS cells were resuspended in R10
without FBS and phenol red (imagingmedia) and resuspended in
imaging media at ∼50,000 cells/150 μl (0.33e6/ml). 50,000 YTS
cells plated in 150 μl imaging media and incubated at 37°C for
exactly 20 min. After, cells were immediately fixed with 4% PFA
for 20 min at room temperature. Cell were then washed once
with PBS and permeabilized with 0.1% Triton X-100 in PBS for
10 min at room temperature. After three additional PBS washes,
cells were stained with phalloidin-Alexa Fluor 568 (1:50, A12380;
ThermoFisher Scientific) for ≥1 h and cells were imaged there-
after without buffer exchange. Imaging was done on a GE Del-
taVision OMX-SR microscope under structured illumination
microscopy–total internal reflection fluorescence (SIM-TIRF)
mode using a 60×/1.42 PlanApoN objective and a pco.edge 4.2
camera. Images were then reconstructed in GE Softworx using
experimentally measured OTF files. Filopodia were manually
counted for cells that spread onto the surface on ImageJ. Cells
with retraction fibers and not filopodia were omitted from
calculation.
Immune cytotoxicity assay for NK cell lines and Pt 2 and Pt 3
For the NK cell line, a chromium-based assay was used. For Pt 2,
the DELFIA cytotoxicity assay was used as described below. For
Pt 3, a flow cytometric–based cytotoxicity assay was performed
similarly to that previously described (Bryceson et al., 2009;
Valiathan et al., 2012). Target cells (721.221) were incubated
with 100 μCi of 51Cr (sodium chromate in normal saline,
NEZ030005MC; PerkinElmer) for 1 h at 37°C, washed three
times in complete R10, and resuspended in complete R10 at a
final concentration of 105 cells/ml. Unlabeled effector YTS cells
were washed once in complete R10 and resuspended to a final
concentration of 106/ml. 105 (200 μl) effector cells were plated
into the first well of a 96-well, round-bottomed polystyrene
tissue culture–treated plate and serially diluted 1:2, except for
the spontaneous and total lysis control wells, which contain
only target cells. 104 51Cr signal from the LumaPlate was read
using a TopCount NXT (PerkinElmer) at the conditions indi-
cated by the manufacturer. Percent lysis is calculated as:
[(TopCount measured cpm − spontaneously released cpm)/
(total cpm − spontaneously released cpm)] × 100. Total cpmwas
derived from a target containing well that was lysed with 1%
IGEPAL (I3021; Sigma-Aldrich) in water.
The DELFIA cytotoxicity assay is based on loading cells with
an acetoxymethyl ester of a fluorescence enhancing ligand. After
the ligand has penetrated the cell membrane the ester bonds are
hydrolyzed within the cell to form a hydrophilic ligand, which
no longer passes through the membrane. After cytolysis, the
released ligand is introduced to a europium solution to form a
fluorescent chelate. Themeasured signal correlates directly with
the amount of lysed cells. 100 µl of loaded target cells (5,000
cells) is pipetted into a round-bottomed sterile plate, and 100 µl
effector cells of varying cell concentration is added. An E/T ratio
from 6:1 to 100:1 is commonly used for NK cells. Additional wells
containing only target cells are plated for detection of back-
ground, spontaneous release, and maximum release. Cells are
then incubated 2 and 3 h in a humidified 5% CO2 atmosphere at
Lam et al. Journal of Experimental Medicine 2795







slo Biologisk user on 14 January 2020
37°C. After incubation, the plate is centrifuged for 5 min at
500 ×g. 20 µl the supernatant is transferred to a flat-bottomed
plate with 200 µl Eu solution, the plate is shaken at 250 rpm for
15 min, and fluorescence is measured. Percent lysis is calculated
as: [(TopCount measured cpm − spontaneously released cpm)/
(total cpm − spontaneously released cpm)] × 100. To measure
spontaneous release, incubate the target cells (100 µl) with
100 µl of medium instead of effector cells. After centrifugation,
transfer 20 µl of the supernatant to the flat-bottomed plate and
add 200 µl Eu solution. Shake for 15 min and measure. To
measure maximum release, incubate the target cells (100 µl)
with 100 µl of medium supplemented with 10 µl of lysis buffer.
After centrifugation, transfer 20 µl of the supernatant to the flat-
bottomed plate and add 200 µl Eu solution. Shake for 15 min and
measure.
Transwell migration assay for immune cells
A standard Boyden chamber assay was used. Corning trans-
well polycarbonate membrane cell culture inserts (6.5 mm, 5-
µm pore polycarbonate, 3421; Corning) were coated overnight
with 10 µg/ml fibronectin in PBS at 4°C. YTS cells were
washed once using complete R10 and resuspended to a final
concentration of 2–4e6 cells/ml. 600 µl of complete R10 sup-
plemented with 100 ng/ml SDF1a/CXCL12 (300-28A; Pepro-
tech) chemoattractant was plated into a 24-well tissue
culture–treated plate. Fibronectin was removed from the
transwell, and the transwell was placed into the wells con-
taining CXCL12-supplemented media. 100 µl (200,000–
400,000 cells) YTS cells were plated onto the upper chamber of
the transwell. The cells were incubated at 37°C for 4 h. After
incubation, the cells were counted by measuring the volume in
the lower chamber and counting the number of events at me-
dium speed for 1 min on an LSR Fortessa Flow Cytometer. The
live events were gated for based on forward scatter (FSC) and
side scatter (SSC) and used for the migration measurement. The
percent migration was calculated as the number of cells that
migrated into the lower chamber divided by the number of cells
in a control well (input cell count) containing the same number
of cells but no transwell.
Immune conjugation assay
YTS NK cells and 721.221 target cells were washed once with
complete R10. YTS cells were then resuspended in PBS at 1e6/ml
and incubated with efluor 450 (#65-0842-85; 1:1,000, 10 min,
and 37°C; eBioscience). 721.221 cells were resuspended in PBS at
1e6/ml and incubated with Cell Trace CFSE (#C34554; 1:2,000,
10 min, and 37°C). Both labeled cells were then washed once
with complete R10 and counted. Labeled YTS cells were re-
suspended to 1e6/ml and labeled 721.221 cells resuspended to
2e6/ml in complete R10. Cells were then combined at an E/T
ratio of 1:2 (100,000 YTS cells:200,000 721.221 cells) and incu-
bated at 37°C for 0, 5, 10, 30, and 60 min. The conjugation re-
actionwas stopped by vortexing for 3 s and fixed with 4% PFA in
PBS for ≥10 min before acquisition. Cells were then counted on a
BD LSR Fortessa flow cytometer and gated based on negative and
single-positive control cells. At least 20,000 live cells were
counted based on FSC/SSC gating. Percent conjugation was
calculated as: (double-positive cells)/(single-positive eFluor
450/YTS cells + double-positive cells) × 100.
Peripheral blood immunophenotype
All flow cytometric analyses were performed on EDTA blood
samples within 24 h of venipuncture. After red blood cell
lysis with ammonium chloride, lymphocytes were washed,
resuspended in PBS, and stained with the following mouse anti-
human antibodies to identify T and B cell subsets: CD45RA APC-
H7 (clone T6D11; Miltenyi Biotec), CD3 PerCP (clone BW264/56;
Miltenyi Biotec), CCR7 PE (clone 3D12; eBioscience), CD4 APC
(clone OKT4; Becton Dickinson), CD8 PE-Cy7 (clone RPA-T8;
Becton Dickinson), CD19 PE-CY7 (clone SJ25C1; Becton Dick-
inson), CD16 PE (clone 3G8), CD56 PE, CD27 FITC (clone M-T271,
Becton Dickinson), TCR α-beta APC (clone T10B9; Becton Dick-
inson), TCR gamma-delta FITC (11F3; Miltenyi Biotec), CD21 PE
(clone B-ly4; Becton Dickinson), CD24 PE (clone ML5; Becton
Dickinson), IgD FITC (clone IA6-2; Becton Dickinson), Goat F(ab)
2 anti-Human IgM (µ)-Alexa Fluor 647 (Jackson Immuno-
Research), and CD38 FITC (clone HIT2; Becton Dickinson). Cells
were incubated with the appropriate antibody cocktail for
30 min at 4°C and then washed with PBS and resuspended in
PBS for flow cytometric acquisition. At least 50,000 events were
acquired within the lymphogate. Data were acquired on a
FACSCanto II (Becton Dickinson) and analyzed with FlowJo
software (Tree Star).
Dendritic cell flow cytometric analysis
Dendritic cell analysis was performed with the Blood Dendritic
cell enumeration kit (#130-091-086; Miltenyi Biotec). This assay
is based on dendritic cell–specific surface antigens CD303
(BDCA-2), CD141 (BDCA-3), and CD1c (BDCA-1). Three distinct
dendritic cell subsets were identified in whole blood: plasma-
cytoid dendritic cells as CD303+ (FITC clone: AC144, BDCA-2),
type 1 myeloid dendritic cells (MDC1s) as CD1c+ (PE clone: AD5-
8E7, BDCA-1), and type 2 myeloid dendritic cells (MDC2s) as
CD141+ (APC clone: Ad4-14H12, BDCA-3) surface expression.
Gate exclusion for CD19, CD14, and dead cells was performed.
After 10 min of incubation in ice with the mix of antibodies, red
blood cells were lysed. Cells were washed with PBS, fixed with
1% PFA for 10 min, acquired with a FACSCanto II (Becton
Dickinson), and analyzed with FlowJo software (Tree Star Inc.;
version 8.8.6). At least 106 total events were acquired.
Clinical flow cytometry for BM analysis/composition
The detailed protocol for whole BM staining has been previously
reported (Basso-Ricci et al., 2017). In brief, Precision Count
beads (BioLegend)were added to 100 μl of P1 BM sample to allow
absolute quantification of hematopoietic cell subsets, and red
blood cell lysis was performed. The lysed sample was labeled
with fluorescent antibodies for CD3-BV605, CD56-PE-Cy5, CD14-
BV510, CD61/41-PE-Cy7, CD135-PE, CD34-BV421, CD45RA-APC-
Cy7 (BioLegend), CD33-BB515, CD66b-BB515, CD38-BUV737,
CD45-BUV395, CD90-APC, CD10-BV786, CD11c-BV650, CD19-
APCR700, CD7-PE-Cy5.5, and CD71-BV711 (BD Biosciences).
Titration assays were performed to assess the best antibody
concentration. After surface marking, the cells were incubated
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with PI (BioLegend) to stain dead cells. All samples were ac-
quired using a BD LSR Fortessa (BD Bioscience) flow cytometer
after calibration with SPHERO rainbow calibration particles
(Spherotech), and raw data were collected using BD FACSDIVA
software. The data were subsequently analyzed with FlowJo
software, and the graphical output was automatically generated
using GraphPad Prism.
Functional characterization of proliferation and migration of
CD34+ cells
Purification of CD34+ cells was performed by two steps of im-
munomagnetic selection (CD34+ microbeads, 130–097-047; Mil-
tenyi Biotec). For proliferation, 104 BM CD34+ cells were
stimulated with stem cell factor (SCF; 100 ng/ml) or a growth
factor mixture (SCF 300 ng/ml, thrombopoietin 100 ng/ml, IL3
60 ng/ml). Proliferation was evaluated at day 5 of stimulation by
16 h liquid scintillation counting of 3H-thymidine (Amersham
Biosciences). The stimulation index was calculated as the ratio
between stimulated and nonstimulated cells. For the transwell
migration assay, 0.5 × 106 peripheral blood lymphocytes or 0.5 ×
104 BM CD34+ cells were seeded on a transwell chambers in
presence of SDF1-α/CXCL12 (100 ng/ml; Peprotech). Migration
was assessed after 3 h. To evaluate clonogenic potential of
CDC42− cells, 2 × 105 BM mononuclear cells as well as 103 BM
CD34+ cells were plated in Methocult medium (H4434; Stemcell
Technologies), and the number of colony-forming units per cell
was scored at day 14 to determine number and type of colonies.
BM mononuclear cells stimulation and
cytokine measurements
BM mononuclear cells were isolated from HD (n = 3) and Pt BM
and were left unstimulated or stimulated with LPS (10 µg/ml)
for 5 h, with or without the addition of ATP (1 mM) for an ad-
ditional hour. Secreted cytokines were measured by in condi-
tioned media. Plasma and supernatant levels of IFNγ, CXCL9,
and IL-6 were assessed using enzyme-linked immunosorbent
assays with human Duoset ELISA kits, and IL-1β plasma levels
were measured using the high-sensitivity quantikine ELISA kit
(all purchased from R&D Systems). Plasma IL-18 levels were
measured using an ELISA kit obtained from MBL.
C. elegans studies
WT cdc-42 cDNA (open reading frame clone R07G3.1; Thermo-
Fisher Scientific) was cloned into the pPD49.83 heat shock–
inducible vector (a kind gift of Andrew Fire, Stanford University,
Stanford, CA). The c.556_558AAG>TGT trinucleotide substitu-
tion (p.K186C corresponding to human p.R186C) was introduced
by site-directed mutagenesis (Stratagene). Germline transfor-
mation and genetic crosses were performed using standard
techniques. Constructs were injected at a concentration of
100 ng/ml. The pJM67 plasmid (pelt-2::NLS::GFP; 30 ng/ml) was
used as coinjection marker. To explore vulval defects, synchro-
nized animals from three independent lines for each construct
were grown at 20°C and heat shocked (33°C, 90 min followed by
30°C, 30 min) in parallel at the early (Muv and Vul) or mid (Pvl)
L3 larval stages. Adults were scored blindly at a Leica MZ10F
dissectingmicroscope to check for the presence of Pvl phenotype,
multiple ectopic pseudovulvae (Muv phenotype) and lack of a
vulva (Vul phenotype). After each cross, the genotype was con-
firmed by Sanger sequencing. Isogenic worms that had lost the
transgene were cloned separately and used as controls. Micros-
copy observations were performed with a Nikon Eclipse 80i in-
strument equipped with Nomarski differential interference
contrast optics on live animals mounted on 2% agarose pads
containing 10 mM sodium azide as anesthetic. The N2 (Bristol)
and PS21 (let-23(sy1), let-23/EGFR hypomorphic allele) strains
were provided by the Caenorhabditis Genetics Center, which is
funded by the National Institutes of Health Office of Research
Infrastructure Programs (P40 OD010440).
Statistical analyses
Data are represented as means ± SD or SEM where indicated.
Statistical analyses were conducted in GraphPad Prism. WB of
patient CDC42 expression intensity measurements and protein
localization intensity measurements were analyzed with the
Student’s t test. GTPase function assays were analyzed using a
Student’s t test. For variance analysis in pull-down assays, an
ordinary one-way ANOVA was performed using the Sidak’s
multiple comparison test. Proliferation assays were analyzed
using either a two-way ANOVA with Dunnett’s multiple com-
parisons for patient fibroblasts. Migration assays were assessed
using a Student’s t test (for YTS NK cell and primary fibroblasts)
or a two-way ANOVA with Tukey’s multiple comparisons (for
NIH-3T3 cells). Multipolarity cell counts, filopodia number, and
filopodia length were assessed using a Welch’s t test. NK cell
cytotoxicity was assessed using the Mann–Whitney U test of
three pooled replicates. NK cell conjugation was assessed using a
Welch’s t test. For C. elegans studies, P values were calculated
using two-tailed Fisher’s exact test. All remaining assays were
performed with n of ≤2. Statistical significance is indicated with
asterisks (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001)
for all tests except two-tailed Fisher’s exact test (*, P < 0.005;
**, P < 0.00002, ***, P < 1.2e−6).
Online supplemental material
Table S1 reports clinical laboratory data for Pt 1 and Pt 2. Table
S2 shows the hematological and immunological profiles of Pt 1–3.
Table S3 provide WES/WGS metrics and data output. Table S4
reports on the vulval phenotypes in transgenic C. elegans ex-
pressing WT CDC-42 or the K186C, R68Q, and A159V disease-
causing mutants. Table S5 reports on the clonogenic assay of BM
cells from Pt 1.
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